Free of Complexing Proteins - Enough for Low Immunogenicity of Botulinum Neurotoxin Formulations? A Comparison of Excipients

被引：0
|
作者：
Martin, Michael U. [1 ]
Frevert, Juergen [2 ]
机构：
[1] Justus Liebig Univ Giessen, D-35390 Giessen, Germany
[2] Merz Pharmaceut GmbH, Frankfurt, Germany
来源：
TOXICON | 2024年 / 237卷
关键词：
BotulinumtoxinA; Coretox; DaxibotulintoxinA-Lanm; Excipients; Immunogenicity; IncobotulinumtoxinA;
D O I：
10.1016/j.toxicon.2024.107447
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：54 / 55
页数：2
相关论文
共 50 条
  • [1] Complexing Protein-Free Botulinum Neurotoxin A Formulations: Implications of Excipients for Immunogenicity
    Martin, Michael Uwe
    Frevert, Juergen
    Tay, Clifton Ming
    TOXINS, 2024, 16 (02)
  • [2] Is there a role for complexing proteins in pharmaceutical botulinum neurotoxin formulations?
    Eisele, Karl-Heinz
    Mander, Gerd J.
    Taylor, Harold V.
    Grein, Swen
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 64 (02) : AB27 - AB27
  • [3] Stability of Xeomin®, a preparation of botulinum neurotoxin type A, free of complexing proteins
    Grein, S.
    Mander, G. J.
    Grafe, S.
    MOVEMENT DISORDERS, 2007, 22 : S18 - S18
  • [4] Botulinum Neurotoxin Type A Free of Complexing Proteins (XEOMIN®) in Focal Dystonia
    Wolfgang H. Jost
    Jörg Blümel
    Susanne Grafe
    Drugs, 2007, 67 : 669 - 683
  • [5] Botulinum neurotoxin type A free of complexing proteins (XEOMIN®) in focal dystonia
    Jost, Wolfgang H.
    Bluemel, Joerg
    Grafe, Susanne
    DRUGS, 2007, 67 (05) : 669 - 683
  • [6] Efficacy and Safety of NT 201 (Botulinum Neurotoxin Free from Complexing Proteins) in Blepharospasm
    Jankovic, Joseph
    Comella, Cynthia
    Hanschmann, Angelika
    Grafe, Susanne
    NEUROLOGY, 2009, 72 (11) : A346 - A346
  • [7] Neurophysiological double-blind trial of a botulinum neurotoxin type A free of complexing proteins
    Wohlfarth, Kai
    Mueller, Christian
    Sassin, Irena
    Comes, Georg
    Grafe, Susanne
    CLINICAL NEUROPHARMACOLOGY, 2007, 30 (02) : 86 - 94
  • [8] Comparison of botulinum neurotoxin type A formulations in Asia
    Frevert, Juergen
    Ahn, Ki Young
    Park, Mee Young
    Sunga, Owen
    CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2018, 11 : 327 - 331
  • [9] Effects of botulinum-neurotoxin-complexing proteins on lymphatic cells
    Wang, L.
    Sun, Y.
    Singh, B. R.
    TOXICON, 2013, 68 : 102 - 102
  • [10] Complexing proteins are not required for stability of botulinum neurotoxin type A preparations
    Grein, S.
    Fink, K.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 285 : S299 - S299
12345